Nicole is the CEO and founder of Altopa, maker of the Oblend, a patented counter-top device which enables healthcare providers and individuals to find, customize, and create precise, consistent cannabis and other therapeutic products. Using the Oblend mobile app, users can find customize, and create recipes from dozens of on-board canisters filled with ingredients such as THC, CBD, myrcene, and pinene. Then the Oblend mixes and dispenses these ingredients very precisely and creates products such as vapes, tinctures, and topicals. If the user likes the product, she can save the recipe and share it with her friends. The user can also adjust the ingredients so, over time, the user is experiencing personalized blends that are perfect for each person’s body.
From 2008-2014, Nicole was the CFO of TearScience, a medical device company that develops disruptive medical diagnostic and treatment devices to treat dry eye disease. During 2010, when TearScience was pre-revenue and pre-FDA approval and in the midst of a national financial crisis, Nicole raised the largest equity financing in the nation for a medical device company. Shortly after closing the $45M Series C financing and TearScience’s FDA clearance, Nicole became acting CEO of TearScience. TearScience commercialized in North America, Europe, Asian, and Latin America. The company hired 150 employees, raised over $125M, and achieved a $30M revenue run rate within three years. Under Nicole’s leadership, TearScience became the fastest growing company in NC and was recently acquired by Johnson & Johnson Vision, a division of Abbot Medical.
Nicole spent over a decade with Ernst & Young. She was senior manager of the entrepreneurial services team and key player in multiple IPO and M&A transactions. She was awarded CFO of the Year in RTP, NC and has raised over $150 million for start-up and emerging growth companies. She has a consistent record of commercializing disruptive products, spurring rapid sales growth, and positioning companies for a successful exit.